Evotec SE (XTER:EVT) EBIT per Share : €-0.50 (TTM As of Mar. 2024)

View and export this data going back to 1999. Start your Free Trial

What is Evotec SE EBIT per Share?

Evotec SE's EBIT per Share for the three months ended in Mar. 2024 was €-0.14. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 was €-0.50.

During the past 12 months, the average EBIT per Share Growth Rate of Evotec SE was -338.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Evotec SE's EBIT per Share or its related term are showing as below:

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Evotec SE was 152.00% per year. The lowest was -38.10% per year. And the median was 16.80% per year.

XTER:EVT's 3-Year EBIT Growth Rate is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 7.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Evotec SE's EBIT for the three months ended in Mar. 2024 was €-24.1 Mil.

Evotec SE EBIT per Share Historical Data

The historical data trend for Evotec SE's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE EBIT per Share Chart

Evotec SE Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT per Share

Get a 7-Day Free Trial

0.43

0.22

1.48

-0.80

-0.39

Evotec SE Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT per Share	Get a 7-Day Free Trial															-0.02	-0.10	-0.15	-0.12	-0.14

Evotec SE EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Evotec SE's EBIT per Share for the fiscal year that ended in Dec. 2023 is calculated as

	EBIT per Share		(A: Dec. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-68.854	/	176.917
=	-0.39

Evotec SE's EBIT per Share for the quarter that ended in Mar. 2024 is calculated as

	EBIT per Share		(Q: Mar. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-24.109	/	177.301
=	-0.14

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.50

Evotec SE (XTER:EVT) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Evotec SE EBIT per Share Related Terms

Thank you for viewing the detailed overview of Evotec SE's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE (XTER:EVT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (XTER:EVT) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

EVO:USA EVOTF:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Austria

Address

Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419

Website

https://www.evotec.com

Evotec SE is a drug discovery partnership company providing solutions to pharmaceutical & biotechnology companies, academic institutions as well as foundations, and not-for-profit organizations. The company offers its services in the area of neuronal diseases, diabetes & its complications, pain, inflammation, oncology, infectious diseases, respiratory & fibrosis, rare disease, and women's health. Its business segments are EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone drug discovery services on a typical fee-for-service basis or integrated drug discovery collaborations. The EVT Innovate segment develops drug discovery programs and assets, both internally and through academic collaborations. The majority of its revenue is derived from the EVT Execute segment.

Executives

Dr. Werner Lanthaler

Board of Directors

Evotec SE (XTER:EVT) Headlines

From GuruFocus

Eaton Vance Tax-Advantaged Dividend Income Fund January 2021 Distribution

By PRNewswire PRNewswire • 01-15-2021

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 10-20-2023

EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND's Dividend Analysis

By GuruFocus Research • 01-22-2024

Unveiling the Dividend Performance of EATON VANCE TAX ADVANTAGED DIVIDEND INCOME FUND (EVT)

By GuruFocus Research • 09-21-2023